Recursion Pharmaceuticals, Inc.RXRXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -57.54% | +9.30% | +32.62% | -80.16% | +687.81% |
| Gross Profit Growth | -1214.80% | -404.69% | -120.33% | -274.38% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +44.12% | +70.65% | +72.32% | +58.18% | +56.75% |
| Weighted Average Shares Diluted Growth | +44.12% | +70.65% | +72.32% | +58.18% | +56.75% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +1489.08% | +1674.68% | +755.34% | +871.62% | -49.87% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +121.60% | +133.98% | +67.86% | +92.64% | +1.76% |
| Book Value per Share Growth | +54.93% | +36.43% | -8.74% | +26.18% | -30.28% |
| Debt Growth | +114.11% | +82.27% | -2.00% | -9.10% | -28.14% |
| R&D Expense Growth | +41.52% | +91.88% | +74.00% | +62.28% | -15.25% |
| SG&A Expenses Growth | +153.42% | +74.00% | +46.56% | +10.25% | -56.39% |